Symptomatic Obstructive Hypertrophic Cardiomyopathy clinical trials

Explore recruiting symptomatic obstructive hypertrophic cardiomyopathy clinical trials.

Recruiting symptomatic obstructive hypertrophic cardiomyopathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Symptomatic Obstructive Hypertrophic Cardiomyopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adolescents (age 12 years to < 18 years) with Symptomatic Obstructive Hypertrophic Cardiomyopathy (SCOUT-HCM)

Germany, Spain, Italy, Ireland, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2/3 Multicenter, Randomized, Double-blind, Placebo-controlled and Open-label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Spain, Italy, Ireland

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Denmark, Italy, Hungary, Germany, Spain, Netherlands +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

MEMENTO-A Phase 3b/4 Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to assess the impact on Myocardial Structure with Cardiac Magnetic Resonance Imaging (CMR)

Hungary, Finland, Spain, France, Greece, Italy +5 more

Phase III and phase IV (Integrated) EU CTIS Study details

A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction (MERCUTIO)

Poland, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Symptomatic Obstructive Hypertrophic Cardiomyopathy trials by city

Symptomatic Obstructive Hypertrophic Cardiomyopathy in Toronto Symptomatic Obstructive Hypertrophic Cardiomyopathy in Vancouver Symptomatic Obstructive Hypertrophic Cardiomyopathy in Montreal Symptomatic Obstructive Hypertrophic Cardiomyopathy in Calgary Symptomatic Obstructive Hypertrophic Cardiomyopathy in Edmonton Symptomatic Obstructive Hypertrophic Cardiomyopathy in Ottawa Symptomatic Obstructive Hypertrophic Cardiomyopathy in Winnipeg Symptomatic Obstructive Hypertrophic Cardiomyopathy in Quebec City Symptomatic Obstructive Hypertrophic Cardiomyopathy in Hamilton Symptomatic Obstructive Hypertrophic Cardiomyopathy in Kitchener Symptomatic Obstructive Hypertrophic Cardiomyopathy in London Symptomatic Obstructive Hypertrophic Cardiomyopathy in Halifax Symptomatic Obstructive Hypertrophic Cardiomyopathy in New York Symptomatic Obstructive Hypertrophic Cardiomyopathy in Los Angeles Symptomatic Obstructive Hypertrophic Cardiomyopathy in Chicago Symptomatic Obstructive Hypertrophic Cardiomyopathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease